Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $527 from $485 and keeps an Outperform rating on the shares. Rezdiffra sales of $287M beat consensus estimates, driven by robust demand, with more than 29,500 patients now on the therapy in the U.S., the analyst tells investors in a research note. The firm is looking forward to Madrigal’s presence and MASH leadership at the Liver Meeting, which is kicking off later this week, where Rezdiffra will be featured in numerous presentations covering efficacy, safety, real-world use, quality of life improvements, early biomarkers, and durability of fibrosis regression.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Q3 2025 Growth
- Madrigal Pharmaceuticals: Strong Market Performance and Strategic Positioning Drive Buy Rating
- Cantor upgrades Madrigal to Overweight on 2026 growth potential
- Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street